Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis
Objective To evaluate the impacts of the 2017 adjustment of National Reimbursement Drug List (NRDL) on orphan drugs hospital procurement volumes and spending in China.Design We used an interrupted time series design covering the period from 2016 to 2018 to analyse changes in hospital procurement vol...
Main Authors: | Yu Xie, Hua Xing, Zihao Wang, Hongbin Yi, Fenghao Shi, Liping Kuai, Dongyan Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-10-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/13/10/e064811.full |
Similar Items
-
Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study
by: Hong Zhu, et al.
Published: (2022-07-01) -
Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
by: Hans-Georg Eichler, et al.
Published: (2023-01-01) -
Pricing and reimbursement of orphan drugs: the need for more transparency
by: Simoens Steven
Published: (2011-06-01) -
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
by: Ewa Stawowczyk, et al.
Published: (2019-11-01) -
Trends in individual reimbursement of orphan drugs in Latvia in 2008–2011
by: Logviss K., et al.
Published: (2014-01-01)